TY - JOUR
T1 - Outcomes of Operative Treatment for Adult Cervical Deformity
T2 - A Prospective Multicenter Assessment with 1-Year Follow-up
AU - Ailon, Tamir
AU - Smith, Justin S.
AU - Shaffrey, Christopher I.
AU - Kim, Han Jo
AU - Mundis, Gregory
AU - Gupta, Munish
AU - Klineberg, Eric
AU - Schwab, Frank
AU - Lafage, Virginie
AU - Lafage, Renaud
AU - Passias, Peter
AU - Protopsaltis, Themistocles
AU - Neuman, Brian
AU - Daniels, Alan
AU - Scheer, Justin K.
AU - Soroceanu, Alex
AU - Hart, Robert
AU - Hostin, Rick
AU - Burton, Douglas
AU - Deviren, Vedat
AU - Albert, Todd J.
AU - Riew, K. Daniel
AU - Bess, Shay
AU - Ames, Christopher P.
N1 - Funding Information:
fellowship support; DePuy Synthes—consultant; Stryker—consultant; Globus— consultant. Disclosures for Dr Hart: Globus—personal fees; Medtronic—grants; Seaspine—personal fees; DePuy Synthes—personal fees; CSRS—board member; ISSG—Executive Committee; ISSLS—board member; OHSU—patent. Disclosures for Dr Hostin: DePuy Synthes—consultant; Nuvasive—research support; Seeger—research support; DJO—research support. Disclosures for Dr Burton: DePuy Synthes—consultant, royalties, research support. Disclosures for Dr Deviren: Nuvasive—consultant, grants; Guidepoint—consultant; OREF— grants; AOSpine—grants; Globus—grants. Disclosures for Dr Albert: DePuy Synthes—royalties, consultant; Zimmer Biomet—royalties; Paradigm—stock; In Vivo—stock; Biometrix—stock; Invuity—stock; Spinicity—stock; Gentis— stock. Disclosures for Dr Riew: Amedica—other financial or material support (royalties, patents, etc.); AOSpine—research support, advisory board or panel, other financial or material support (royalties, patents, etc.); Benevue—other financial or material support (royalties, patents, etc.); Biomet—other financial or material support (royalties, patents, etc.); Broadwater—other financial or material support (royalties, patents, etc.); Cerapedics—research support; Expanding Orthopedics—other financial or material support (royalties, patents, etc.); Expert Testimony—consultant; Medtronic—research support, other financial or material support (royalties, patents, etc.); Medyssey—other financial or material support (royalties, patents, etc.); Nexgen Spine—other financial or material support (royalties, patents, etc.); Osprey—other financial or material support (royalties, patents, etc.); Paradigm Spine—other financial or material support (royalties, patents, etc.); PSD—other financial or material support (royalties, patents, etc.); Selby Spine—other financial or material support (royalties, patents, etc.); Spinal Kinetics—other financial or material support (royalties, patents, etc.); Spineology—other financial or material support (royalties, patents, etc.); Vertiflex—other financial or material support (royalties, patents, etc.). Disclosures for Dr Bess: K2 Medical—consultant, royalties, research support; Allosource—consultant; Pioneer—royalties; Innovasis— royalties, research support; Nuvasive—royalties, research support; DePuy Synthes Spine—research support; Stryker—research support. Disclosures for Dr Ames: DePuy Synthes—consultant; Medtronic—consultant; Stryker—consultant, royalties; Zimmer Biomet—royalties; Fish & Richardson, PC—patents.
Funding Information:
The International Spine Study Group (ISSG) is funded through research grants from DePuy Spine and individual donations. Disclosures for Dr Smith: Zimmer Biomet—consultant, honorarium for teaching, royalties; Nuvasive—consultant, honorarium for teaching; Cerapedics—consultant; K2M—honorarium for teaching; AOSpine—fellowship funding; NREF— fellowship funding. Disclosures for Dr Shaffrey: Medtronic—royalties, patents, consultant; Nuvasive—royalties, patents, consultant, stock holder; Zimmer Biomet—royalties, patents, consultant; K2M—consultant; Stryker— consultant; In Vivo—consultant; NIH—grants; Department of Defense—grants; ISSG—grants; DePuy Synthes—grants; AO—grants. Disclosures for Dr Kim: K2M—consultant; Zimmer Biomet—consultant; ISSGF—research funding; CSRS—research funding; HSS Journal—board membership; ASJ—board membership; GSJ—board membership. Disclosures for Dr Mundis: Nuvasive— consulting, royalties, research funding (not paid to Dr Mundis); K2M— consulting, royalties; DePuy Synthes—honorarium; DePuy Synthes/ISSG— research funding (not paid to Dr Mundis). Disclosures for Dr Gupta: DePuy Synthes—royalties, consultant, honorarium for lectures; Orthofix—consultant, honorarium for lectures. Disclosures for Dr Klineberg: DePuy—consulting; Stryker—consulting; AOSpine—paid speaker, fellowship support; K2M—paid speaker. Disclosures for Dr Schwab: Grants: SRS, DePuy Spine (through ISSGF); Speaking/teaching arrangements, consulting: Zimmer-Biomet, NuVasive, K2M, MSD, Medicrea; Board of Directors, Share holder: Nemaris INC; Royalties: K2M, MSD. Disclosures for Dr V Lafage: Depuy Synthes—paid lectures; Nuvasive— paid lectures; K2M—paid lectures; Medtronic—paid lectures; Nemaris—Board member and shareholder. Disclosures for Dr Passias: Medicrea—consultant. Disclosures for Dr Protopsaltis: Consulting: Medicrea, Globus, Innovasis, Nuvasive; Research support to my institution: Zimmer Spine, Cervical Spine Research Society. Disclosures for Dr Neuman: Depuy Synthes—research grant. Disclosures for Dr Daniels: Orthofix—consultant, research support,
Publisher Copyright:
© 2017 by the Congress of Neurological Surgeons.
PY - 2018/11/1
Y1 - 2018/11/1
N2 - BACKGROUND: Despite the potential for profound impact of adult cervical deformity (ACD) on function and health-related quality of life (HRQOL), there are few high-quality studies that assess outcomes of surgical treatment for these patients. OBJECTIVE: To determine the impact of surgical treatment for ACD on HRQOL. METHODS: We conducted a prospective cohort study of surgically treated ACD patients eligible for 1-yr follow-up. Baseline deformity characteristics, surgical parameters, and 1-yr HRQOL outcomes were assessed. RESULTS: Of 77 ACD patients, 55 (71%) had 1-yr follow-up (64% women, mean age of 62 yr, mean Charlson Comorbidity Index of 0.6, previous cervical surgery in 47%). Diagnoses included cervical sagittal imbalance (56%), cervical kyphosis (55%), proximal junctional kyphosis (7%) and coronal deformity (9%). Posterior fusion was performed in 85% (mean levels = 10), and anterior fusion was performed in 53% (mean levels = 5). Three-column osteotomywas performed in 24%of patients.One year following surgery,ACDpatients had significant improvement in Neck Disability Index (50.5 to 38.0, P<.001), neck pain numeric rating scale score (6.9 to 4.3, P<.001), EuroQol 5 dimension (EQ-5D) index (0.51 to 0.66, P< .001), and EQ-5D subscores: mobility (1.9 to 1.7, P=.019), usual activities (2.2 to 1.9, P=.007), pain/discomfort (2.4 to 2.1, P < .001), anxiety/depression (1.8 to 1.5, P = .014). CONCLUSION: Based on a prospective multicenter series of ACD patients, surgical treatment provided significant improvement in multiple measures of pain and function, including Neck Disability Index, neck pain numeric rating scale score, and EQ-5D. Further follow-up will be necessary to assess the long-term durability of these improved outcomes.
AB - BACKGROUND: Despite the potential for profound impact of adult cervical deformity (ACD) on function and health-related quality of life (HRQOL), there are few high-quality studies that assess outcomes of surgical treatment for these patients. OBJECTIVE: To determine the impact of surgical treatment for ACD on HRQOL. METHODS: We conducted a prospective cohort study of surgically treated ACD patients eligible for 1-yr follow-up. Baseline deformity characteristics, surgical parameters, and 1-yr HRQOL outcomes were assessed. RESULTS: Of 77 ACD patients, 55 (71%) had 1-yr follow-up (64% women, mean age of 62 yr, mean Charlson Comorbidity Index of 0.6, previous cervical surgery in 47%). Diagnoses included cervical sagittal imbalance (56%), cervical kyphosis (55%), proximal junctional kyphosis (7%) and coronal deformity (9%). Posterior fusion was performed in 85% (mean levels = 10), and anterior fusion was performed in 53% (mean levels = 5). Three-column osteotomywas performed in 24%of patients.One year following surgery,ACDpatients had significant improvement in Neck Disability Index (50.5 to 38.0, P<.001), neck pain numeric rating scale score (6.9 to 4.3, P<.001), EuroQol 5 dimension (EQ-5D) index (0.51 to 0.66, P< .001), and EQ-5D subscores: mobility (1.9 to 1.7, P=.019), usual activities (2.2 to 1.9, P=.007), pain/discomfort (2.4 to 2.1, P < .001), anxiety/depression (1.8 to 1.5, P = .014). CONCLUSION: Based on a prospective multicenter series of ACD patients, surgical treatment provided significant improvement in multiple measures of pain and function, including Neck Disability Index, neck pain numeric rating scale score, and EQ-5D. Further follow-up will be necessary to assess the long-term durability of these improved outcomes.
KW - Cervical deformity
KW - Outcomes
KW - Quality of life
KW - Spinal deformity
KW - Surgery
UR - http://www.scopus.com/inward/record.url?scp=85053566960&partnerID=8YFLogxK
U2 - 10.1093/neuros/nyx574
DO - 10.1093/neuros/nyx574
M3 - Article
C2 - 29281107
AN - SCOPUS:85053566960
SN - 0069-4827
VL - 83
SP - 1031
EP - 1039
JO - Clinical Neurosurgery
JF - Clinical Neurosurgery
IS - 5
ER -